|
1
|
D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky
EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM,
Kernis JT, et al: Survival in patients with primary pulmonary
hypertension: Results from a national prospective registry. Ann
Intern Med. 115:343–349. 1991.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gall H, Felix JF, Schneck FK, Milger K,
Sommer N, Voswinckel R, Franco OH, Hofman A, Schermuly RT,
Weissmann N, et al: The giessen pulmonary hypertension registry:
Survival in pulmonary hypertension subgroups. J Heart Lung
Transplant. 36:957–967. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Escribano-Subias P, Blanco I,
López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P,
Castillo-Palma MJ, Segovia J, Gómez-Sanchez MA and Barberà JA:
REHAP investigators: Survival in pulmonary hypertension in Spa in:
Insights from the Spanish registry. Eur Respir J. 40:596–603.
2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Galiè N, Humbert M, Vachiery JL, Gibbs S,
Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf AV,
Beghetti M, et al: 2015 ESC/ERS guidelines for the diagnosis and
treatment of pulmonary hypertension: The joint task force for the
diagnosis and treatment of pulmonary hypertension of the european
society of cardiology (ESC) and the european respiratory society
(ERS): Endorsed by: Association for european paediatric and
congenital cardiology (AEPC), international society for heart and
lung transplantation (ISHLT). Eur Heart J. 37:67–119.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Barberà JA, Román A, Gómez-Sánchez MÁ,
Blanco I, Otero R, López-Reyes R, Otero I, Pérez-Peñate G, Sala E
and Escribano P: Guidelines on the diagnosis and treatment of
pulmonary hypertension: Summary of recommendations. Arch
Bronconeumol. 54:205–215. 2018.(In English, Spanish). PubMed/NCBI View Article : Google Scholar
|
|
6
|
Barst RJ, McGoon M, Torbicki A, Sitbon O,
Krowka MJ, Olschewski H and Gaine S: Diagnosis and differential
assessment of pulmonary arterial hypertension. J Am Coll Cardiol.
43:S40–S47. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lai YC, Potoka KC, Champion HC, Mora AL
and Gladwin MT: Pulmonary arterial hypertension: The clinical
syndrome. Circ Res. 115:115–130. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gupta H, Ghimire G and Naeije R: The value
of tools to assess pulmonary arterial hypertension. Eur Respir Rev.
20:222–235. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chester AH, Yacoub MH and Moncada S:
Nitric oxide and pulmonary arterial hypertension. Glob Cardiol Sci
Pract. 2017(14)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cracowski JL and Leuchte HH: The potential
of biomarkers in pulmonary arterial hypertension. Am J Cardiol. 110
(Suppl 6):S32–S38. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shao D, Park JE and Wort SJ: The role of
endothelin-1 in the pathogenesis of pulmonary arterial
hypertension. Pharmacol Res. 63:504–511. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang X, Xu Q, Li T, Rong Y, Hong W, Huang
Y and Guo X: Intratracheal administration of isosorbide dinitrate
improves pulmonary artery pressure and ventricular remodeling in a
rat model of heart failure following myocardial infarction. Exp
Ther Med. 14:1399–1408. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Montani D, Souza R, Binkert C, Fischli W,
Simonneau G, Clozel M and Humbert M: Endothelin-1/endothelin-3
ratio: A potential prognostic factor of pulmonary arterial
hypertension. Chest. 131:101–108. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Simon M, Battistini B, Kim YJ and Tsang J:
Plasma levels of endothelin-1, big endothelin-1 and thromboxane
following acute pulmonary air embolism. Respir Physiol Neurobiol.
138:97–106. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Satwiko MG, Ikeda K, Nakayama K, Yagi K,
Hocher B, Hirata K and Emoto N: Targeted activation of endothelin-1
exacerbates hypoxia-induced pulmonary hypertension. Biochem Biophys
Res Commun. 465:356–362. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Vizza CD, Letizia C, Badagliacca R, Poscia
R, Pezzuto B, Gambardella C, Nona A, Papa S, Marcon S, Mancone M,
et al: Relationship between baseline ET-1 plasma levels and outcome
in patients with idiopathic pulmonary hypertension treated with
bosentan. Int J Cardiol. 167:220–224. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fukumoto S, Hanazono K, Miyasho T, Endo Y,
Kadosawa T, Iwano H and Uchide T: Serum big endothelin-1 as a
clinical marker for cardiopulmonary and neoplastic diseases in
dogs. Life Sci. 118:329–332. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ibe JCF, Zhou Q, Chen T, Tang H, Yuan JXJ,
Raj JU and Zhou G: Adenosine monophosphate-activated protein kinase
is required for pulmonary artery smooth muscle cell survival and
the development of hypoxic pulmonary hypertension. Am J Respir Cell
Mol Biol. 49:609–618. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Evans AM, Hardie DG, Peers C and Mahmoud
A: Hypoxic pulmonary vasoconstriction: Mechanisms of
oxygen-sensing. Curr Opin Anaesthesiol. 24(13)2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu Y, Liu L, Zhang Y, Wang G, Han D, Ke R,
Li S, Feng W and Li M: Activation of AMPK inhibits pulmonary
arterial smooth muscle cells proliferation. Exp Lung Res.
40:251–258. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Agard C, Rolli-Derkinderen M,
Dumas-de-La-Roque E, Rio M, Sagan C, Savineau JP, Loirand G and
Pacaud P: Protective role of the antidiabetic drug metformin
against chronic experimental pulmonary hypertension. Br J
Pharmacol. 158:1285–1294. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Omura J, Satoh K, Kikuchi N, Satoh T,
Kurosawa R, Nogi M, Otsuki T, Kozu K, Numano K, Suzuki K, et al:
Protective roles of endothelial AMP-activated protein kinase
against hypoxia-induced pulmonary hypertension in mice. Circ Res.
119:197–209. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
National Researrch Council: Guide for the
Care and Use of Laboratory Animals. 8th edition. National Academies
Press. Washingthon DC, 2010.
|
|
24
|
Gomez-Arroyo JG, Farkas L, Alhussaini AA,
Farkas D, Kraskauskas D, Voelkel NF and Bogaard HJ: The
monocrotaline model of pulmonary hypertension in perspective. Am J
Physiol Lung Cell Mol Physiol. 302:L363–L369. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nakata TM, Tanaka R, Yoshiyuki R, Fukayama
T, Goya S and Fukushima R: Effects of single drug and combined
short-term administration of sildenafil, pimobendan, and nicorandil
on right ventricular function in rats with monocrotaline-induced
pulmonary hypertension. J Cardiovasc Pharmacol.
65(640)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bogdan S, Seferian A, Totoescu A,
Dumitrache-Rujinski S, Ceausu M, Coman C, Ardelean CM, Dorobantu M
and Bogdan M: Sildenafil reduces inflammation and prevents
pulmonary arterial remodeling of the monocrotaline-induced disease
in the Wistar rats. Maedica. 7(109)2012.PubMed/NCBI
|
|
27
|
Wang Y, Tian W, Xiu C, Yan M, Wang S and
Mei Y: Urantide improves the structure and function of right
ventricle as determined by echocardiography in
monocrotaline-induced pulmonary hypertension rat model. Clin
Rheumatol. 38:29–35. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tawa M, Furukawa T, Tongu H, Sugihara M,
Taguwa S, Yamanaka M, Yano Y, Matsumori H, Kitada R, Sawano T, et
al: Stimulation of nitric oxide-sensitive soluble guanylate cyclase
in monocrotaline-induced pulmonary hypertensive rats. Life Sci.
203:203–209. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Breitling S, Krauszman A, Parihar R,
Walther T, Friedberg MK and Kuebler WM: Dose-dependent, therapeutic
potential of angiotensin-(1-7) for the treatment of pulmonary
arterial hypertension. Pulm Circ. 5:649–657. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Pacagnelli FL, Sabela AKD, Mariano TB,
Ozaki GAT, Castoldi RC, Carmo EM, Carvalho RF, Tomasi C, Okoshi K
and Vanderlei LCM: Fractal dimension in quantifying
experimental-pulmonary-hypertension-induced cardiac dysfunction in
rats. Arq Bras Cardiol. 107:33–39. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Karasu-Minareci E, Ozbudak IH, Ozbilim G
and Sadan G: Acute effects of vardenafil on pulmonary artery
responsiveness in pulmonary hypertension. ScientificWorldJournal.
2012(718279)2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bae HK, Lee H, Kim KC and Hong YM: The
effect of sildenafil on right ventricular remodeling in a rat model
of monocrotaline-induced right ventricular failure. Korean J
Pediatr. 59:262–270. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tsukamoto A, Uchida K, Maesato S, Sato R,
Kanai E and Inomata T: Combining isoflurane anesthesia with
midazolam and butorphanol in rats. Exp Anim. 65:223–230.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Aimbire F, Penna SC, Rodrigues KC,
Lopes-Martins RAB and Serté JAA: Effect of hydroalcoholic extract
of zingiber officinalis rhizomes on LPS-induced rat airway
hyperreactivity and lung inflammation. Prostaglandins Leukot Essent
Fatty Acids. 77:129–138. 2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Albrecht M, Henke J, Tacke S, Markert M
and Guth B: Effects of isoflurane, ketamine-xylazine and a
combination of medetomidine, midazolam and fentanyl on
physiological variables continuously measured by telemetry in
wistar rats. BMC Vet Res. 198:10–23. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gades NM, Danneman PJ, Wixson SK and
Tolley EA: The magnitude and duration of the analgesic effect of
morphine, butorphanol, and buprenorphine in rats and mice. Contemp
Top Lab Anim Sci. 39:8–13. 2000.PubMed/NCBI
|
|
37
|
Lee JH, Park BK, Oh KS, Yi KY, Lim CJ, Seo
HW and Lee BH: A urotensin II receptor antagonist, KR36676,
decreases vascular remodeling and inflammation in experimental
pulmonary hypertension. Int Immunopharmacol. 40:196–202.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kimura K, Daimon M, Morita H, Kawata T,
Nakao T, Okano T, Lee SL, Takenaka K, Nagai R, Yatomi Y and Komuro
I: Evaluation of right ventricle by speckle tracking and
conventional echocardiography in rats with right ventricular heart
failure. Int Heart J. 56:349–353. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Itoh T, Nagaya N, Fujii T, Iwase T,
Nakanishi N, Hamada K, Kangawa K and Kimura H: A combination of
oral sildenafil and beraprost ameliorates pulmonary hypertension in
rats. Am J Respir Crit Care Med. 169:34–38. 2004.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hirose S, Hosoda Y, Furuya S, Otsuki T and
Ikeda E: Expression of vascular endothelial growth factor and its
receptors correlates closely with formation of the plexiform lesion
in human pulmonary hypertension. Pathol Int. 50:472–479.
2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Tuder RM, Groves B, Badesch DB and Voelkel
NF: Exuberant endothelial cell growth and elements of inflammation
are present in plexiform lesions of pulmonary hypertension. Am J
Pathol. 144:275–285. 1994.PubMed/NCBI
|
|
42
|
Dean A, Nilsen M, Loughlin L, Salt IP and
MacLean MR: Metformin reverses development of pulmonary
hypertension via aromatase inhibition. Hypertension. 68:446–454.
2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhai C, Shi W, Feng W, Zhu Y, Wang J, Li
S, Yan X, Wang Q, Zhang Q, Chai L, et al: Activation of AMPK
prevents monocrotaline-induced pulmonary arterial hypertension by
suppression of NF-κB-mediated autophagy activation. Life Sci.
208:87–95. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hattori Y, Suzuki K, Hattori S and Kasai
K: Metformin inhibits cytokine-induced nuclear factor kappaB
activation via AMP-activated protein kinase activation in vascular
endothelial cells. Hypertension. 47:1183–1188. 2006.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lalich J and Merkow L: Pulmonary arteritis
produced in rats by feeding crotalaria spectabilis. Lab Invest.
10:744–750. 1961.PubMed/NCBI
|
|
46
|
Yamaguchi K, Kanai Y, Asano K, Takasugi T,
Tanaka T, Yasuoka M and Hosoda Y: Temporal alterations of
endothelial-vasodilator functions in lung injury induced by
monocrotaline. Respir Physiol. 107:47–58. 1997.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Rubens C, Ewert R, Halank M, Wensel R,
Orzechowski HD, Schultheiss HP and Hoeffken G: Big endothelin-1 and
endothelin-1 plasma levels are correlated with the severity of
primary pulmonary hypertension. Chest. 120:1562–1569.
2001.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Stangl K, Dschietzig T, Richter C, Laule
M, Stangl V, Tanis E, Baumann G and Felix SB: Pulmonary release and
coronary and peripheral consumption of big endothelin and
endothelin-1 in severe heart failure: Acute effects of vasodilator
therapy. Circulation. 102:1132–1138. 2000.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ,
Zhou Q, Wei W, Zhu HQ and Wang Y: Sitagliptin inhibits endothelin-1
expression in the aortic endothelium of rats with
streptozotocin-induced diabetes by suppressing the nuclear
factor-κB/IκBα system through the activation of AMP-activated
protein kinase. Int J Mol Med. 37:1558–1566. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Barnes PJ and Karin M: Nuclear factor-κB:
A pivotal transcription factor in chronic inflammatory diseases. N
Engl J Med. 336:1066–1071. 1997.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Tei C, Dujardin KS, Hodge DO, Bailey KR,
McGoon MD, Tajik AJ and Seward SB: Doppler echocardiographic index
for assessment of global right ventricular function. J Am Soc
Echocardiogr. 9:838–847. 1996.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Seyfarth HJ, Pankau H, Hammerschmidt S,
Schauer J, Wirtz H and Winkler J: Bosentan improves exercise
tolerance and Tei index in patients with pulmonary hypertension and
prostanoid therapy. Chest. 128:709–713. 2005.PubMed/NCBI View Article : Google Scholar
|
